Aspirin’s benefit in thwarting colon cancer is driven by a gene mutation that makes tumor cells less sensitive to the drug’s effects, according to a study that may lead to personalized prevention strategies. Andrew Chan, HMS associate professor of medicine at Massachusetts General Hospital, is one of the authors.
